Inhibikase Therapeutics Stock Performance
| IKT Stock | USD 2.72 0.04 1.45% |
On a scale of 0 to 100, Inhibikase Therapeutics holds a performance score of 6. The company retains a Market Volatility (i.e., Beta) of -0.64, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Inhibikase Therapeutics are expected to decrease at a much lower rate. During the bear market, Inhibikase Therapeutics is likely to outperform the market. Please check Inhibikase Therapeutics' potential upside, and the relationship between the total risk alpha and kurtosis , to make a quick decision on whether Inhibikase Therapeutics' current trending patterns will revert.
Risk-Adjusted Performance
6 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Inhibikase Therapeutics are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unsteady forward-looking signals, Inhibikase Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (1.45) | Five Day Return (4.56) | Year To Date Return (17.33) | Ten Year Return (95.42) | All Time Return (95.42) |
Last Split Factor 1:6 | Last Split Date 2023-06-30 |
1 | Inhibikase Therapeutics director Bellini acquires 2m in stock | 10/23/2024 |
2 | Wednesdays Insider Activity Top Buys and Sells in US Stocks | 10/24/2024 |
3 | Jefferies starts Inhibikase Therapeutics shares with Buy on drug potential | 11/08/2024 |
4 | Inhibikase Therapeutics files for secondary offering of common stock | 11/18/2024 |
5 | Inhibikase Adjusts and Terminates Stock Offering Agreement - TipRanks | 12/05/2024 |
6 | Disposition of 21853 shares by Milton Werner of Inhibikase Therapeutics at 2.02 subject to Rule 16b-3 | 12/09/2024 |
7 | Inhibikase Therapeutics Trading 3.4 percent Higher - Time to Buy - MarketBeat | 12/27/2024 |
8 | Acquisition by Berman Dennis N of 172191 shares of Inhibikase Therapeutics at 1.45 subject to Rule 16b-3 | 01/03/2025 |
9 | Disposition of 43707 shares by Ofarrell Elizabeth G. of Inhibikase Therapeutics at 5.57 subject to Rule 16b-3 | 01/17/2025 |
| Begin Period Cash Flow | 7.2 M |
Inhibikase |
Inhibikase Therapeutics Relative Risk vs. Return Landscape
If you would invest 222.00 in Inhibikase Therapeutics on October 20, 2024 and sell it today you would earn a total of 50.00 from holding Inhibikase Therapeutics or generate 22.52% return on investment over 90 days. Inhibikase Therapeutics is generating 0.5456% of daily returns assuming volatility of 6.6978% on return distribution over 90 days investment horizon. In other words, 59% of stocks are less volatile than Inhibikase, and above 90% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Inhibikase Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Inhibikase Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Inhibikase Therapeutics, and traders can use it to determine the average amount a Inhibikase Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0815
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | IKT | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.7 actual daily | 59 59% of assets are less volatile |
Expected Return
| 0.55 actual daily | 10 90% of assets have higher returns |
Risk-Adjusted Return
| 0.08 actual daily | 6 94% of assets perform better |
Based on monthly moving average Inhibikase Therapeutics is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Inhibikase Therapeutics by adding it to a well-diversified portfolio.
Inhibikase Therapeutics Fundamentals Growth
Inhibikase Stock prices reflect investors' perceptions of the future prospects and financial health of Inhibikase Therapeutics, and Inhibikase Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Inhibikase Stock performance.
| Return On Equity | -1.5 | ||||
| Return On Asset | -0.76 | ||||
| Operating Margin | (238.85) % | ||||
| Current Valuation | 188.34 M | ||||
| Shares Outstanding | 69.36 M | ||||
| Price To Book | 26.46 X | ||||
| Price To Sales | 2,406 X | ||||
| Revenue | 260.5 K | ||||
| Gross Profit | (11.98 M) | ||||
| EBITDA | (19.91 M) | ||||
| Net Income | (19.03 M) | ||||
| Cash And Equivalents | 32.21 M | ||||
| Cash Per Share | 1.28 X | ||||
| Total Debt | 622 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 7.56 X | ||||
| Book Value Per Share | 1.77 X | ||||
| Cash Flow From Operations | (18.09 M) | ||||
| Earnings Per Share | (3.07) X | ||||
| Market Capitalization | 191.44 M | ||||
| Total Asset | 14.51 M | ||||
| Retained Earnings | (66.9 M) | ||||
| Working Capital | 10.77 M | ||||
About Inhibikase Therapeutics Performance
Assessing Inhibikase Therapeutics' fundamental ratios provides investors with valuable insights into Inhibikase Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Inhibikase Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 54.6 K | 57.3 K | |
| Return On Tangible Assets | (1.18) | (1.24) | |
| Return On Capital Employed | (2.09) | (1.98) | |
| Return On Assets | (1.18) | (1.24) | |
| Return On Equity | (1.99) | (1.89) |
Things to note about Inhibikase Therapeutics performance evaluation
Checking the ongoing alerts about Inhibikase Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Inhibikase Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Inhibikase Therapeutics is way too risky over 90 days horizon | |
| Inhibikase Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the last year's revenue of 260.5 K. Reported Net Loss for the year was (19.03 M) with loss before taxes, overhead, and interest of (11.98 M). | |
| Inhibikase Therapeutics has about 32.21 M in cash with (18.09 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.28. | |
| Inhibikase Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Disposition of 43707 shares by Ofarrell Elizabeth G. of Inhibikase Therapeutics at 5.57 subject to Rule 16b-3 |
- Analyzing Inhibikase Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Inhibikase Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Inhibikase Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Inhibikase Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Inhibikase Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Inhibikase Therapeutics' stock. These opinions can provide insight into Inhibikase Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Inhibikase Stock Analysis
When running Inhibikase Therapeutics' price analysis, check to measure Inhibikase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibikase Therapeutics is operating at the current time. Most of Inhibikase Therapeutics' value examination focuses on studying past and present price action to predict the probability of Inhibikase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibikase Therapeutics' price. Additionally, you may evaluate how the addition of Inhibikase Therapeutics to your portfolios can decrease your overall portfolio volatility.